The Antiplatelet Effects of a New Nitroderivative of Acetylsalicylic Acid - An In Vitro Study of Inhibition on the Early Phase of Platelet Activation and on TXA₂ Production

Summary

We studied in vitro the antiplatelet activity of a new nitroderivative chemically related to acetylsalicylic acid: 2 acetoxybenzoate 2-[l-nitroxy-methyl]-phenyl ester (NCX 4016), in order to identify any effects due to the release of nitric oxide and the blockade of cyclooxygenase

The effects of scalar doses of NCX 4016 on the early phase of platelet activation, platelet aggregation and thromboxane A₂ production were investigated. We observed inhibitory effects of NCX 4016 on platelet adhesion (IC₅₀ = 7.3 × 10⁻⁵ M), platelet cytosolic calcium concentration, assayed by fluorescent probe Fura 2, and the expression of glycoprotein IMIIa (CD41 / α_IIbβ₃) (IC₅₀ = 3.4 × 10⁻⁵ M) and P-selec-tin (CD62 / GMP-140) (IC50 = 4.9 × 10⁻⁵ M) measured by flow cytometry. NCX 4016 also prevented thrombin-induced platelet aggregation (IC50 = 3.9 × 10⁻⁵ M). None of these parameters were affected by acetylsalicylic acid. These inhibitory activities of NCX 4016 were abolished by oxyhaemoglobin and methylene blue. Intracellular cyclic GMP observed during thrombin-induced aggregation was increased by incubation with NCX 4016. These results appear to be attributable to the release of nitric oxide, which activates soluble platelet guanylyl-cyclase and promotes intracellular cyclic GMP increase. NCX 4016 almost completely inhibited platelet thromboxane A₂ production and arachidonic acid-induced platelet aggregation. This also occurred in the presence of oxyhaemoglobin and methylene blue, indicating that its antiplatelet activity can be attributed not only to nitric oxide release but also to cyclo-oxygenase inhibition.

• References

• 1 Ignarro LJ, Ross G, Tillisch J. Pharmacology of endothelium-derived nitric oxide and nitrovasodilators. West J Med 1991; 154: 51-62
• 2 Stamler JS, Loscalzo J. The antiplatelet effects of organic nitrates and related compounds in vitro and in vivo and their relevance to cardiovascular disorders. J Am Coll Cardiol 1991; 18: 529-536
• 3 Wallace JL, Reuter B, Cicala C, McKnight W, Grisham NB, Cirino G. Novel NSAID derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterol 1994; 107: 173-179
• 4 Lechi C, Minuz P, Gaino S, Tommasoli R, Del Soldato P, Benoni G, Zuliani V, Lechi A. Antiaggregating and vasodilatory effects of a new nitroderi-vative of acetylsalicylic acid. Eur J Clin Invest 1995; 25: A 234
• 5 Minuz P, Lechi C, Tommasoli R, Gaino S, Degan M, Zuliani V, Bonapace S, Benoni G, Adami A, Cuzzolin L, Lechi A. Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. Thromb Res 1995; 80: 367-376
• 6 Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-315
• 7 Hallam TJ, Thompson NT, Scrutton MC, Rink TJ. The role of cytoplasmic free calcium in the responses of Quin 2-loaded human platelets to vasopressin. Biochem J 1984; 221: 897-901
• 8 Bellavite P, Andrioli G, Guzzo P, Arigliano P, Chirumbolo S, Manzato F, Santonastaso C. A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem 1994; 216: 444-450
• 9 Rajiv J, Engji H, Grunfeld S, Welch KMA. Dimethyl-sulfoxide and stimulation of platelet cytoplasmic calcium. Thromb Haemost 1989; 61: 326
• 10 Pollock WK, Rink TJ, Irvine RF. Liberation of ³H arachidonic acid and changes in cytosolic free calcium in fura-2-loaded human platelets stimulated by ionomycin and collagen. Biochemical J 1986; 235: 869-877
• 11 Rink TJ, Smith SV, Tsien RY. Cytoplasmic free Ca²⁺ in human platelets: Ca²⁺ threshold and Ca-independent activation for shape change and secretion. FEBS Lett 1982; 148: 21-26
• 12 Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann N Y Acad Sci 1993; 677: 293-308
• 13 Chronos NAF, Wilson DJ, Janes SL, Hutton RA, Buller NP, Goodall AH. Aspirin does not affect the flow cytometryc detection of fibrinogen binding to, or release of a-granules or lysosomes from, human platelets. Clin Sci 1994; 87: 575-580
• 14 Salvemini D, Korbut R, Ånggard E, Vane J. Immediate release of a nitric oxide-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci USA 1990; 87: 2593-2597
• 15 Sils D, Rodgers SE, Lloyd JV, Wilson KM, Siebert DM, Bochner F. Inhibition of platelet aggregation and thromboxane production by low concentrations of aspirin in vitro. Clin Sci 1988; 74: 491-497
• 16 Salvemini D, Pistelli A, Vane J. Conversion of glyceryl trinitrate to nitric oxide in tolerant and non-tolerant smooth muscle and endothelial cells. Br J Pharmacol 1993; 108: 162-169
• 17 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327
• 18 Anderson TJ, Meredith IT, Ganz P, Selwyn AP, Yeung AC. Nitric oxide and nitro vasodilators: similarities, differences and potential interactions. J Am Coll Cardiol 1994; 24: 555-566
• 19 Schafer AI, Alexander RW, Handin RI. Inhibition of platelet function by organic nitrate vasodilators. Blood 1980; 55: 649-654
• 20 Mehta J, Mehta P. Comparative effects of nitroprusside and nitroglycerin on platelet aggregation in patients with heart failure. J Cardiovasc Pharmacol 1980; 2: 25-33
• 21 Fitzgerald DJ, Roy L, Robertson RM, FitzGerald GA. The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans. Circulation 1984; 70: 297-302
• 22 Stamler J, Cunnigham M, Loscalzo J. Reduced thiols and the effects intra-venus nitroglycerin on platelet aggregation. Am J Cardiol 1988; 62: 377-380
• 23 Diodati J, Theroux P, Latour JC, Lacoste L, Lam JYT, Waters D. Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol 1990; 17: 683-688
• 24 Langford EJ, Brown AS, Wainwright RJ, de Beider AJ, Thomas MR, Smith REA, Radomski MW, Martin JF, Moncada S. Inhibition of platelet activity by S-nitroso-glutathione during coronary angioplasty. Lancet 1994; 344: 1458-1460
• 25 Buechler WA, Ivanova K, Wolfram G, Drummer C, Heim JM, Gerzer R. Soluble guanylyl cyclase and platelet function. Ann N Y Acad Sci 1994; 714: 151-157
• 26 Ahlner J, Axelsson KL, Karlsson JOG, Andersson RGG. Glyceryl trinitrate inhibits phosphatidyl inositol hydrolysis and protein kinase C activity in bovine mesenteric artery. Life Sci 1988; 43: 1241-1248
• 27 Geiger J, Nolte C, Walter U. Regulation of calcium mobilization and entry in human platelets by endothelium-derived factors. Am J Physiol 1994; 267 (Cell Physiol 36) C236-C244
• 28 Okamoto Y, Ninomiya H, Miwa S, Masaki T. Capacitative Ca²⁺ entry in human platelets is resistant to nitric oxide. Biochem Biophys Res Commun 1995; 212: 90-96
• 29 Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, Wagner DD, Furie B. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989; 59: 305-312
• 30 Calvete JJ. Clues for understandig the structure and function of a prototyp-ic human integrin: the platelet glycoprotein Ilb/IIIa complex. Thromb Haemost 1994; 72: 1-15
• 31 Ginsberg MH, Du X, Plow EF. Inside-out integrin signalling. Curr Opin Cell Biol 1992; 4: 766-771
• 32 Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-886
• 33 Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898-1902
• 34 Gerzer R, Karrenbrock W, Siess W, Heim GM. Direct comparison of the effects of nitroprusside, SIN 1 and various nitrates on platelet aggregation and soluble guanylate-cyclase activity. Thromb Res 1988; 52: 11-21
• 35 Salvemini D, Radzisewski W, Korbut R, Vane J. The use of oxyhaemoglo-bin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol 1990; 101: 991-995
• 36 Martin W, Villani GM, Jothianandan D, Furchgott RF. Selective blockade of endothelium-dependent and glyceryl-trinitrate-induced relaxation by hemoglobin and methylene blue in the rabbit aorta. J Pharmacol and ExperimTher 1985; 232: 708-716
• 37 Durante W, Kroll MH, Vanhoutte PM, Sheffer AY. Endothelium-derived relaxing factor inhibits thrombin-induced platelet aggregation by inhibiting platelet phospholipase C. Blood 1992; 79: 110-116
• 38 Tsai A. How does NO activate heme proteins?. FEBS Lett 1994; 341: 141-145
• 39 Salvemini D, Misko TP, Masferrer JR, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclo-oxygenase enzymes. Proc Natl Acad Sci 1993; 90: 7240-7244
• 40 Davidge ST, Baker PN, McLauglin MK, Roberts JM. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ Res 1995; 77: 274-283
• 41 Stadler J, Harbrecht BG, Di Silvio M, Curran RD, Jordan ML, Simmons RL, Billiar TR. Endogenus nitric oxide inhibits the synthesis of cyclo-oxygenase products and interleukin-6 by rat Kupfer cells. J Leukoc Biol 1993; 53: 165-172
• 42 Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Coinduction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol 1995; 114: 1335-1342
• 43 Cuzzolin L, Adami A, Degan M, Crivellente F, Bonapace S, Minuz P, Benoni G. Effect of single and repeated doses of a new nitroderivative of acetylsalicylic acid on platelet TXA₂ production in rats. Life Sci 1996; 58: 207-210